poisar

Stock

Gilead Sciences, Inc. GILD

$138.36+0.16%

Overview

GILD market data

Price History

GILD price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
19.42
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$6.78
Diluted earnings per share over the trailing twelve months.
Beta
0.33
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
2.4%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-10.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$108.46 – $157.29
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $165.2B · P/B 6.71 · P/S 5.42.

Company News

10 captured
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’Benzinga · Aug 12, 2026, 12:44 PM
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M PaymentBenzinga · Aug 11, 2026, 8:22 PM
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, SnowflakeBenzinga · Aug 11, 2026, 5:01 PM
Top C-suite Executives Recognized at the 2026 National ORBIE AwardsGlobenewswire Inc · Aug 7, 2026, 3:15 PM
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'Benzinga · Aug 6, 2026, 7:41 AM
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?The Motley Fool · Aug 5, 2026, 8:15 PM
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123Benzinga · Aug 5, 2026, 4:16 PM
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price TargetBenzinga · Aug 5, 2026, 12:52 PM
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price TargetBenzinga · Aug 5, 2026, 10:02 AM
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This YearBenzinga · Aug 4, 2026, 9:17 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock